Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Terns names Amy Burroughs CEO

Plus: Disc hires Jean Franchi as CFO, promotes Jonathan Yu to COO, and updates from Domain, Enable Injections and Alchemab

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
February 9, 2024 2:12 AM UTC

Cancer and obesity company Terns Pharmaceuticals Inc. (NASDAQ:TERN) named Amy Burroughs as CEO and a member of the board. Burroughs was CEO of Cleave Therapeutics Inc., and executive in residence at 5AM Ventures.

Hematological disease play Disc Medicine Inc. (NASDAQ:IRON) hired Jean Franchi to succeed Joanne Bryce as CFO, and promoted Jonathan Yu to COO from CBO. Franchi was CFO of Replimune Group Inc. (NASDAQ:REPL) and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK); Bryce will become a consultant to the company...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Alchemab Therapeutics Ltd.

Disc Medicine Inc.

Domain Therapeutics S.A.

Enable Injections Inc.

Terns Pharmaceuticals Inc.